Oruka Therapeutics, Inc.

ORKA

Acquisition of Pre-Merger Oruka On August 29, 2024 (the Merger Closing ), we completed our acquisition (the Merger ) of Oruka Therapeutics, Inc. ( Pre-Merger Oruka ) pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the Merger Agreement ). Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger …

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$6.33B

EPS-$2.26

P/E-42.32

P/FCF-62.55

EV/EBITDA-35.18

FCF Yield–

Div. Yield–

Net Debt/FCF8.6x

Oruka Therapeutics, Inc. intrinsic value

52-Week Range

$26.19$113.08

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$133M

Op. Margin

–

ROIC

-19.08%

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$101M

Op. Cash Flow (TTM)

-$101M

Net Debt

-$871M

Net Cash Position

Cash & Equiv.

$874M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with ORKA

CompareIntrinsic value

NKTXNkarta Inc.

$1.56-6.02%10

TNXPTonix Pharmaceuticals Holding Corp

$5.09-3.60%40

SCYXScynexis, Inc.

$3.72-3.63%40

HROWHarrow Inc.

$28.24-5.84%46

HRTXHeron Therapeutics Inc.

$0.28-3.45%36

RCKTRocket Pharmaceuticals Inc.

$2.44-3.94%10

BBIOBridgeBio Pharma, Inc.

$74.95+5.97%30

LGNDLigand Pharmaceuticals Inc.

$322.75+1.71%36

Held by ETFs

ORKA is in 63 US ETFs. The largest of them, with ORKA's weight in each:

Oruka Therapeutics (ORKA) in three numbers

Quality score: 10/100; Best check: net debt, -$871M. Weakest: return on capital, -19.1%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -42.32; Negative: a loss over the last twelve months. Price to free cash flow -62.55.; Financials

Questions about Oruka Therapeutics

Is Oruka Therapeutics a high-quality business?

Oruka Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$871M, and its weakest is return on capital at -19.1%. The Quality tab shows every check against its target.

Does Oruka Therapeutics (ORKA) pay a dividend?

No. Oruka Therapeutics (ORKA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ORKA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ORKA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.